Premium
Polo‐like kinase and its inhibitors: Ready for the match to start?
Author(s) -
Palmisiano Neil D.,
Kasner Margaret T.
Publication year - 2015
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.24177
Subject(s) - polo like kinase , kinase , in vivo , downregulation and upregulation , mitosis , plk1 , medicine , in vitro , cancer research , cell cycle , biology , bioinformatics , microbiology and biotechnology , cancer , genetics , gene
Polo‐like kinases (Plks) plays a central role in the normal cell cycle and their upregulation has been shown to play a role in the pathogenesis of multiple human cancers. Preclinical work demonstrates that targeting Plk has a significant impact on the treatment of both solid and hematologic malignancies in vitro and in vivo. We review here the basic science and clinical work to date with the Plks as well as future directions with this novel class of mitotic inhibitors. Am. J. Hematol. 90:1071–1076, 2015. © 2015 Wiley Periodicals, Inc.